Workflow
山东药玻(600529) - 2025 Q1 - 季度财报
600529SPG(600529)2025-04-24 12:30

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,242,455,243.50, a decrease of 1.97% compared to ¥1,267,462,044.57 in the same period last year[3] - Net profit attributable to shareholders was ¥223,629,434.88, reflecting a slight increase of 1.29% from ¥220,789,398.54 year-on-year[3] - Basic earnings per share rose to ¥0.34, up 3.03% from ¥0.33 in the same period last year[3] - Net profit for Q1 2025 was CNY 223,629,434.88, an increase of 1.3% compared to CNY 220,789,398.54 in Q1 2024[17] - The net profit attributable to the parent company's shareholders for the current period is CNY 223,629,434.88, compared to CNY 220,789,398.54 in the previous period, reflecting a slight increase[18] - The total comprehensive income for the current period is CNY 223,629,434.88, consistent with the net profit attributable to the parent company[18] Cash Flow - The net cash flow from operating activities decreased significantly by 69.43%, amounting to ¥90,533,209.57 compared to ¥296,176,607.65 in the previous year[3] - Cash flow from operating activities for the current period is CNY 90,533,209.57, a significant decrease from CNY 296,176,607.65 in the previous period[21] - Cash inflow from investment activities is CNY 1,598,445,580.50, compared to CNY 1,220,157,795.45 in the previous period, indicating a strong performance in this area[21] - The net cash flow from investment activities is CNY 10,032,671.59, a recovery from a negative CNY 426,192,878.57 in the previous period[22] - The net increase in cash and cash equivalents for the current period is CNY 104,408,670.45, contrasting with a decrease of CNY 124,950,594.87 in the previous period[22] - The ending balance of cash and cash equivalents is CNY 989,590,032.16, down from CNY 1,161,950,132.81 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,173,365,821.62, showing a slight increase of 0.33% from ¥10,140,009,365.84 at the end of the previous year[4] - Total current assets as of March 31, 2025, were CNY 6,054,844,132.51, slightly up from CNY 5,980,458,741.73 as of December 31, 2024[14] - Total non-current assets decreased to CNY 4,118,521,689.11 from CNY 4,159,550,624.11 as of December 31, 2024[14] - Total liabilities as of March 31, 2025, were CNY 1,943,079,956.55, down from CNY 2,132,239,675.29 as of December 31, 2024[15] - The company reported a decrease in accounts payable to CNY 776,475,750.05 from CNY 903,594,044.08[14] Shareholder Information - Shareholders' equity attributable to shareholders increased by 2.78%, reaching ¥8,230,285,865.07 compared to ¥8,007,769,690.55 at the end of the last year[4] - Shareholders' equity increased to CNY 8,230,285,865.07 as of March 31, 2025, compared to CNY 8,007,769,690.55 as of December 31, 2024[15] - The number of ordinary shareholders at the end of the reporting period was 70,488[6] Expenses and Gains - Total operating costs for Q1 2025 were CNY 982,600,179.31, down 2.1% from CNY 1,004,324,485.10 in Q1 2024[17] - Research and development expenses in Q1 2025 amounted to CNY 49,680,967.32, up 24.4% from CNY 39,921,990.72 in Q1 2024[17] - The company reported a total of ¥9,442,163.87 in non-recurring gains and losses for the period[5] - Investment income saw a significant increase of 104.13%, attributed to the maturity income from structured deposits[5] - The company experienced a 39.39% rise in financial expenses due to decreased interest income and exchange gains[5] Accounting Standards - The company has not reported any net profit from subsidiaries prior to consolidation for the current or previous periods[18] - The company is not applying new accounting standards or interpretations for the current reporting period[22]